The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.
 
Jermaine Coward
Research Funding - AstraZeneca (Inst)
 
Ben Markman
Consulting or Advisory Role - Amgen; Amgen; Bristol-Myers Squibb; Merck
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Amgen (Inst)
Travel, Accommodations, Expenses - Akeso Biopharma
 
Adnan Nagrial
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Roche
Research Funding - Akeso Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst)
 
Afaf Abed
No Relationships to Disclose
 
Imogen Walpole
No Relationships to Disclose